Brilacidin HCl
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319690

CAS#: 1224095-99-1 (HCl)

Description: Brilacidin, also known as PMX30063, is an arylamide foldamer designed to replicate the amphiphilic properties of antimicrobial peptides while solving the problems encountered by peptide-based antimicrobials. Brilacidin, a broad-spectrum antibiotic, has potent Gram positive activity and Gram negative coverage, and is highly effective in treating the 'superbug' methicillin-resistant Staphylococcus aureus (MRSA). Brilacidin has low cytotoxicity against mammalian cells selectively targeting bacteria, directly and rapidly disrupting their membranes, resulting in the bacteria's death. Due to this unique mechanism of action (mimicking the host's natural immune response, proven to be successful in fighting off infections over millions of years of evolution), bacterial antibiotic resistance is less likely to develop.

Chemical Structure

img
Brilacidin HCl
CAS# 1224095-99-1 (HCl)
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 319690
Name: Brilacidin HCl
CAS#: 1224095-99-1 (HCl)
Chemical Formula: C40H54Cl4F6N14O6
Exact Mass: 936.39
Molecular Weight: 1,082.754
Elemental Analysis: C, 44.37; H, 5.03; Cl, 13.10; F, 10.53; N, 18.11; O, 8.87

Price and Availability

Size Price Availability Quantity
1mg USD 80 Ready to ship
5mg USD 150 Ready to ship
10mg USD 250 Ready to ship
25mg USD 550 Ready to ship
50mg USD 950 Ready to ship
100mg USD 1650 Ready to ship
200mg USD 2950 Ready to ship
Bulk inquiry

Related CAS #: 1224095-99-1 (HCl)   1224095-98-0 (free base)    

Synonym: PMX30063; PMX-30063; PMX 30063; Brilacidin; Brilacidin HCl; Brilacidin tetrahydrochloride;

IUPAC/Chemical Name: N4,N6-bis(3-(5-guanidinopentanamido)-2-(((R)-pyrrolidin-3-yl)oxy)-5-(trifluoromethyl)phenyl)pyrimidine-4,6-dicarboxamide tetrahydrochloride

InChi Key: QTHBCQCKYVOFDR-PIJQHSLXSA-N

InChi Code: InChI=1S/C40H50F6N14O6.4ClH/c41-39(42,43)21-13-25(57-31(61)5-1-3-9-53-37(47)48)33(65-23-7-11-51-18-23)27(15-21)59-35(63)29-17-30(56-20-55-29)36(64)60-28-16-22(40(44,45)46)14-26(34(28)66-24-8-12-52-19-24)58-32(62)6-2-4-10-54-38(49)50;;;;/h13-17,20,23-24,51-52H,1-12,18-19H2,(H,57,61)(H,58,62)(H,59,63)(H,60,64)(H4,47,48,53)(H4,49,50,54);4*1H/t23-,24-;;;;/m1..../s1

SMILES Code: O=C(C1=NC=NC(C(NC2=CC(C(F)(F)F)=CC(NC(CCCCNC(N)=N)=O)=C2O[C@H]3CNCC3)=O)=C1)NC4=CC(C(F)(F)F)=CC(NC(CCCCNC(N)=N)=O)=C4O[C@H]5CNCC5.[H]Cl.[H]Cl.[H]Cl.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target: Brilacidin tetrahydrochloride (PMX 30063 tetrahydrochloride) is an anti-infective antimicrobial with MIC90s of 1 and 8 μg/mL for Gram-positive bacteria Streptococcus pneumonia and Streptococcus viridans, and MIC90 of 8 and 4 μg/mL for Gram-negative bacteria Haemophilus influenza and Pseudomonas aeruginosa.
In vitro activity: The potential of brilacidin to exert an antiviral activity against SARS-CoV-2 was assessed using Vero cells as an infection model. The effect of brilacidin treatment on SARS-CoV-2 viral replication was then evaluated in Vero cells by plaque assay. Vero cells were pretreated with brilacidin for 2 h, after which media containing the drug were removed and replaced with virus inoculum (Washington strain 2019-nCoV/USA-WA1/2020). Infection was allowed to progress for 1 h, after which the inoculum was removed and replaced with brilacidin containing media. The data demonstrate that brilacidin treatment resulted in a dose-dependent decrease in infectious viral titer with a maximum of 53% inhibition of virus observed in the presence of the higher concentration of the compound (10 µM) that was tested Reference: Viruses. 2021 Feb 9;13(2):271. https://pubmed.ncbi.nlm.nih.gov/33572467/
In vivo activity: Rabbits treated with BRI 1% wiped their eyes immediately upon instillation after the second dose and continued for every dose thereafter. This behavioral reaction suggested that BRI 1% appeared to be irritating to the eyes upon instillation. BRI 1% also demonstrated corneal (median score = 2.5) and iris toxicity (median score = 7.5). One rabbit treated with BRI 0.25%, vocalized shortly after the 5th dose. BRI also 0.5% reduced CFU in abraded corneas significantly more than in intact corneas (P = 0.005, M-W) suggesting that the corneal epithelium acts as a barrier for penetration. Reference: J Ocul Pharmacol Ther. Jan-Feb 2016;32(1):23-7. https://pubmed.ncbi.nlm.nih.gov/26501484/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 83.3 76.96

Preparing Stock Solutions

The following data is based on the product molecular weight 1,082.75 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Bakovic A, Risner K, Bhalla N, Alem F, Chang TL, Weston WK, Harness JA, Narayanan A. Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture. Viruses. 2021 Feb 9;13(2):271. doi: 10.3390/v13020271. PMID: 33572467; PMCID: PMC7916214. 2. Hu Y, Jo H, DeGrado WF, Wang J. Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell. J Med Virol. 2022 May;94(5):2188-2200. doi: 10.1002/jmv.27616. Epub 2022 Feb 2. PMID: 35080027; PMCID: PMC8930451. 3. Kowalski RP, Romanowski EG, Yates KA, Mah FS. An Independent Evaluation of a Novel Peptide Mimetic, Brilacidin (PMX30063), for Ocular Anti-infective. J Ocul Pharmacol Ther. 2016 Jan-Feb;32(1):23-7. doi: 10.1089/jop.2015.0098. Epub 2015 Oct 26. PMID: 26501484; PMCID: PMC4742993.
In vitro protocol: 1. Bakovic A, Risner K, Bhalla N, Alem F, Chang TL, Weston WK, Harness JA, Narayanan A. Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture. Viruses. 2021 Feb 9;13(2):271. doi: 10.3390/v13020271. PMID: 33572467; PMCID: PMC7916214. 2. Hu Y, Jo H, DeGrado WF, Wang J. Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell. J Med Virol. 2022 May;94(5):2188-2200. doi: 10.1002/jmv.27616. Epub 2022 Feb 2. PMID: 35080027; PMCID: PMC8930451.
In vivo protocol: 1. Kowalski RP, Romanowski EG, Yates KA, Mah FS. An Independent Evaluation of a Novel Peptide Mimetic, Brilacidin (PMX30063), for Ocular Anti-infective. J Ocul Pharmacol Ther. 2016 Jan-Feb;32(1):23-7. doi: 10.1089/jop.2015.0098. Epub 2015 Oct 26. PMID: 26501484; PMCID: PMC4742993.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kowalski RP, Romanowski EG, Yates KA, Mah FS. An Independent Evaluation of a
Novel Peptide Mimetic, Brilacidin (PMX30063), for Ocular Anti-infective. J Ocul
Pharmacol Ther. 2016 Jan-Feb;32(1):23-7. doi: 10.1089/jop.2015.0098. Epub 2015
Oct 26. PubMed PMID: 26501484.


2: Mensa B, Howell GL, Scott R, DeGrado WF. Comparative mechanistic studies of
brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents
Chemother. 2014 Sep;58(9):5136-45. doi: 10.1128/AAC.02955-14. Epub 2014 Jun 16.
PubMed PMID: 24936592; PubMed Central PMCID: PMC4135847.